| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 02/26/2004 | WO2002087419A3 Biological pacemaker |
| 02/26/2004 | WO2002087411A3 Composite scaffolds and methods using same for generating complex tissue grafts |
| 02/26/2004 | WO2002083937A3 Methods using o6-alkylguanine-dna alkyltransferases |
| 02/26/2004 | WO2002083917A8 Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer |
| 02/26/2004 | WO2002083890A3 Use of clya hemolysin for excretion of fusion proteins |
| 02/26/2004 | WO2002083869A3 Product and process for transformation of thraustochytriales microorganisms |
| 02/26/2004 | WO2002083067A9 Prodrugs via acylation with cinnamate |
| 02/26/2004 | WO2002079482A3 In vitro transcribed retroviral genomes, methods for their production and methods of use |
| 02/26/2004 | WO2002079472A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 02/26/2004 | WO2002079440A3 Transgenic mice containing gpcr5-1 gene disruptions |
| 02/26/2004 | WO2002078608A3 A simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome or polyplex for systemic administration of a therapeutic or diagnostic agent |
| 02/26/2004 | WO2002077227A3 Iterative optimization in the design of binding proteins |
| 02/26/2004 | WO2002074808A3 Modified insulin with reduced immunogenicity |
| 02/26/2004 | WO2002070705A3 Human 7tm proteins and polynucleotides encoding them |
| 02/26/2004 | WO2002068600A3 Endogenous and non-endogenous versions of human g protein-coupled receptors |
| 02/26/2004 | WO2002066672A3 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists |
| 02/26/2004 | WO2002066652A3 Ehrlichia ruminantium polypeptides, antigens, polynucleotides, and methods of use |
| 02/26/2004 | WO2002062204A3 Methods for diagnosing and treating heart disease |
| 02/26/2004 | WO2002059345A3 Nucleic acid encoding ion transporter component protein |
| 02/26/2004 | WO2002059263A3 Transgenic animals comprising a humanized immune system |
| 02/26/2004 | WO2002051237A3 Helicobacter proteins, nucleic acids and uses thereof |
| 02/26/2004 | WO2002050277A3 Protein and nucleic acids encoding same |
| 02/26/2004 | WO2002048369A3 Polynucleotide encoding a human potassium channel beta-subunit, k+mbeta1 |
| 02/26/2004 | WO2002046418A3 Lipid-associated molecules |
| 02/26/2004 | WO2002046382A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/26/2004 | WO2002045499A3 Transgenic mice containing deubiquitinated enzyme gene disruptions |
| 02/26/2004 | WO2002045498A3 Transgenic mice containing channel protein target gene disruptions |
| 02/26/2004 | WO2002045496A3 Transenic mice containing frp-rs4 gene disruptions |
| 02/26/2004 | WO2002045494A3 Transgenic mice containing glucagon receptor gene disruptions |
| 02/26/2004 | WO2002045492A3 Transgenic mice containing polycystin-related gene disruptions |
| 02/26/2004 | WO2002043650A3 Systems and methods for delivering interferon to a subject |
| 02/26/2004 | WO2002042487A3 Compositions, methods and kits relating to remodelin |
| 02/26/2004 | WO2002042424A3 Seed-preferred regulatory elements and uses thereof |
| 02/26/2004 | WO2002042336A3 Fgf-affinity chromatography |
| 02/26/2004 | WO2002040656A3 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, and 84234, novel human guanine nucleotide dissociation stimulator, glycosyltransferase, dead type helicase, centaurin, dehydrogenase/reductase, and metal transporter family members and uses thereof |
| 02/26/2004 | WO2002040542A3 58569 and 50111, human anion exchange proteins and methods of use thereof |
| 02/26/2004 | WO2002038775A3 METHODS FOR PRODUCING AND PURIFYING RECOMBINANT α-L-IDURONIDASE |
| 02/26/2004 | WO2002038765A3 Dna encoding bovine immunoglobulin a inducing protein and uses therefor |
| 02/26/2004 | WO2002036831A3 Canola event pv-bngt04(rt73) and compositions and methods for detection thereof |
| 02/26/2004 | WO2002034935A3 In vitro selection of signaling aptamers |
| 02/26/2004 | WO2002034782A3 Endozepine-like polypeptide nov1 and nucleic acid encoding the same |
| 02/26/2004 | WO2002033089A3 Ixodes scapularis tissue factor pathway inhibitor |
| 02/26/2004 | WO2002031152A3 Intracellular signaling molecules |
| 02/26/2004 | WO2002029005A3 Detection of ras mutations |
| 02/26/2004 | WO2002006480A3 Tissue inhibitors of matrix metalloproteinases |
| 02/26/2004 | WO2001088192A3 A method for generating hypermutable organisms |
| 02/26/2004 | WO2001074299A3 Compositions and methods for inhibition of cancer invasion and angiogenesis |
| 02/26/2004 | WO2001066723A3 Hetero-oligomeric g protein-coupled receptors as drug target |
| 02/26/2004 | WO2001057175A3 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides |
| 02/26/2004 | US20040040062 Method for producing human lactoferrin in plant cell culture |
| 02/26/2004 | US20040040061 Corn for administration to animals to elicit immune respone; plant extracts |
| 02/26/2004 | US20040040059 Pectinophora gossypiella (pink bollworm) bacillus thuringiensis toxin receptor BT-R2 |
| 02/26/2004 | US20040040058 Plastid promoters for transgene expression in the plastids of higher plants |
| 02/26/2004 | US20040040057 Plant Myb transcription factor homologs |
| 02/26/2004 | US20040040054 Modifying the expression of a Na+/H+ antiporter coding nucleic acid in the plant ,wherein the plant has an increased tolerance to an environmental stress as compared to a wild type variety of the plant; genetic engineering |
| 02/26/2004 | US20040040053 Method for the preparation of nucleic acid |
| 02/26/2004 | US20040040052 Transgenic organism |
| 02/26/2004 | US20040040051 Generation of non-human mammals by nuclear cloning |
| 02/26/2004 | US20040040050 Combination of Nuclear Transfer (NT) and Embryonic Stem (ES) cell technologies that improves the efficiency of delilvering optimized genetically modified farm animals |
| 02/26/2004 | US20040040049 Reduction in the formation of the complex in the presence of the candidate agent as compared with in the absence of candidate agent indicates the candidate agent inhibits the binding of LBP-2 to the LBP-2 binding molecule |
| 02/26/2004 | US20040040048 Introducing atransgene into an embryo of the animal, which containing a nucleic acid encoding phytase, transplanting the embroy into a pseudopregnanat animal, allowing embryo to develop to term, detecting offspring expressing the transgene |
| 02/26/2004 | US20040040047 Regulated apoptosis using chemically induced dimerization of apoptosis factors |
| 02/26/2004 | US20040040046 Animal models; gene expression inhibition |
| 02/26/2004 | US20040040045 Method of screening for substance preventing or treating diseases in association with malfunction of il-6 family cytokine receptor malfunction |
| 02/26/2004 | US20040039329 Transferring medically effective substances in form of molecules such as DNA, oligos, chemicals, etc., into living cells of humans, animals and/or plants using acoustic energy or through cavitation produced by acoustic energy |
| 02/26/2004 | US20040039201 Functionalized compositions for improved immobilization |
| 02/26/2004 | US20040039188 Systems and methods for the rapid isolation of nucleic acids |
| 02/26/2004 | US20040039187 Chimeric GB virus B (GBV-B) |
| 02/26/2004 | US20040039186 Self-regulated apoptosis of inflammatory cells by gene therapy |
| 02/26/2004 | US20040039185 Novel family member of inhibitor of apoptosis proteins |
| 02/26/2004 | US20040039184 Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
| 02/26/2004 | US20040039175 Comprises HIV/herpes virus promoter sequence |
| 02/26/2004 | US20040039170 Regulation of human g protein-coupled receptor |
| 02/26/2004 | US20040039166 Newly identified polypeptides and polynucleotides encoding such polypeptides referred to as inhibitor of apoptosis proteins (IAPL-3); use in diagnosis and in identifying compounds that may be agonists, antagonists |
| 02/26/2004 | US20040039165 Clostridium difficile polypeptides and uses thereof |
| 02/26/2004 | US20040039164 Invention relates to identification and isolation of novel DNA and to recombinant production of novel polypeptides |
| 02/26/2004 | US20040039162 Gdf-1 |
| 02/26/2004 | US20040039116 A solid support comprising a diol group for bonding to oligonucleotides, proteins, cells, and coupling to substrate with a silane compound |
| 02/26/2004 | US20040039058 Identifying a mammal having elevated concentrations of tumor necrosis factor- alpha and administering stearidonic acid (18:4, n-3) over a time period |
| 02/26/2004 | US20040038926 Antisense modulation of MyD88 expression |
| 02/26/2004 | US20040038925 Inhibition of complement activation and complement modulation by use of modified oligonucleotides |
| 02/26/2004 | US20040038924 Adenovirus serotype 30 (Ad30) |
| 02/26/2004 | US20040038921 Comprises double-stranded oligoribonucleic acid (dsRNA); hammerhead ribozymes |
| 02/26/2004 | US20040038919 Novel gene therapy agent for haemophilia b and its preparation method |
| 02/26/2004 | US20040038902 For therapy of neoplastic disease |
| 02/26/2004 | US20040038901 Essential downstream component of the wingless signaling pathway and therapeutic and diagnostic applications based thereon |
| 02/26/2004 | US20040038896 For diagnosis and therapy |
| 02/26/2004 | US20040038893 Prevention and reduction of blood loss |
| 02/26/2004 | US20040038890 Human voltage-gated potassium channel subunit |
| 02/26/2004 | US20040038888 Functional role and potential therapeutic use of PACAP, VIP and Maxadilan in relation to adult neural stem or progenitor cells |
| 02/26/2004 | US20040038886 Chimeric cytoplasmic signalling molecules derived from cd137 |
| 02/26/2004 | US20040038879 For therapy and prophylaxis of infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma, Parkinson's disease, acute heart failure |
| 02/26/2004 | US20040038877 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 02/26/2004 | US20040038876 For use in therapy and diagnosis |
| 02/26/2004 | US20040038873 Used for the manufacture of medicine for the treatment of developmental disorders, diseases caused by abnormal metabolism of immune system, and cancers |
| 02/26/2004 | US20040038869 Inhibitors of complement activation, their preparation and use |
| 02/26/2004 | US20040038430 Monoclonal antibodies specific for PHF-TAU, hybridomas secreting them, antigen recognition by these antibodies and their applications |
| 02/26/2004 | US20040038427 Method for detecting and/or quantifying first molecules |
| 02/26/2004 | US20040038417 Method for identifying and/or characterizing a (poly)peptide |
| 02/26/2004 | US20040038410 Composition for the preservation of viruses |